Model of End-Stage Liver Disease (MELD) Score as a Predictor of In-Hospital Mortality in Patients with COVID-19: A Novel Approach to a Classic Scoring System.
covid-19
infection
inflammation
meld
mortality
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
22 May 2021
22 May 2021
Historique:
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Background Limited data is available for reliable and accurate predictors of in-hospital mortality in patients diagnosed with COVID-19. Methods This scientific study is a retrospective cohort study of patients without a known history of liver diseases who were hospitalized with COVID-19 viral infection. Patients were stratified into low score groups (Model of End-Stage Liver Disease [MELD] score <10) and high score groups (MELD ≥10). Clinical outcomes were evaluated, including in-hospital mortality, hospital length of stay, and intensive care unit length of stay (ICU LOS). Results Our cohort of 186 COVID-19 positive patients included 88 (47%) women with a mean age of 60 years in the low score group and mean age of 73 years in the high score group. Patients in the high score group were older in age (p<0.0001) and more likely to have history of diabetes mellitus (p=0.0020), stage 3 chronic kidney disease (CKD) (p=0.0013), hypertension (p<0.0001), stroke/transient ischemic attack (TIA) (p=0.0163), asthma (p=0.0356), dementia (p<0.0001), and chronic heart failure (p=0.0055). The in-hospital mortality or discharge to hospice rate was significantly higher in the high-score group as opposed to the low-score group (p=0.0014). Conversely, there was no significant difference among both groups in the hospital length of stay (LOS) and ICU LOS (p=0.6929 and p=0.7689, respectively). Conclusion Patients hospitalized with COVID-19 infection and found to have a MELD score greater than or equal to 10 were found to have a higher mortality as compared to their counterparts. Conversely a low MELD score is a very strong indicator of a more favorable prognosis, indicating hospital survival. We propose using the MELD score as an adjunct for risk stratifying patients diagnosed with COVID-19 without prior history of liver dysfunction.
Identifiants
pubmed: 34178500
doi: 10.7759/cureus.15179
pmc: PMC8216703
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15179Informations de copyright
Copyright © 2021, Stawinski et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Infect Dis. 2020 May;94:81-87
pubmed: 32205284
Int J Infect Dis. 2020 Apr;93:264-267
pubmed: 32114193
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Med Virol. 2020 Oct;92(10):1875-1883
pubmed: 32441789
Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):229-233
pubmed: 32270660
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):107-111
pubmed: 32077660
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Stat Med. 2007 May 10;26(10):2170-83
pubmed: 16927452
J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24
pubmed: 32274342
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Emerg Infect Dis. 2020 Jun;26(6):1337-1339
pubmed: 32150527
J Clin Exp Hepatol. 2013 Mar;3(1):50-60
pubmed: 25755471
Cardiol Res. 2020 Dec;11(6):398-404
pubmed: 33224386
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):100-106
pubmed: 32077659
Gastroenterology. 2003 Jan;124(1):91-6
pubmed: 12512033
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773